TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Sponsor: Aptose Biosciences Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 240 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT03850574 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03850574 Rescue Dossier →